Cargando…

Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study

PURPOSE: Tau pathology is associated with concurrent atrophy and decreased cerebral blood flow (CBF) in Alzheimer’s disease (AD), but less is known about their temporal relationships. Our aim was therefore to investigate the association of concurrent and longitudinal tau PET with longitudinal change...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Denise, Verfaillie, Sander C. J., Bosch, Iris, Brouwer, Iman, Tuncel, Hayel, Coomans, Emma M., Rikken, Roos M., Mastenbroek, Sophie E., Golla, Sandeep S. V., Barkhof, Frederik, van de Giessen, Elsmarieke, van Berckel, Bart N. M., van der Flier, Wiesje M., Ossenkoppele, Rik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250461/ https://www.ncbi.nlm.nih.gov/pubmed/36976303 http://dx.doi.org/10.1007/s00259-023-06196-2

Ejemplares similares

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2022)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2020)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Tau protein spreads through functionally connected neurons in Alzheimer’s disease: a combined MEG/PET study
por: Schoonhoven, Deborah N, et al.
Publicado: (2023)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
por: Verfaillie, Sander CJ, et al.
Publicado: (2020)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
por: Coomans, Emma M., et al.
Publicado: (2021)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis
por: Bocancea, Diana I., et al.
Publicado: (2021)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Grey zone amyloid burden affects memory function: the SCIENCe project
por: Ebenau, J. L., et al.
Publicado: (2020)

Genetically identical twin-pair difference models support the amyloid cascade hypothesis
por: Coomans, Emma M, et al.
Publicado: (2023)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease
por: Adriaanse, Sofie M., et al.
Publicado: (2014)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?
por: Verfaillie, Sander C. J., et al.
Publicado: (2015)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Genetically identical twins show comparable tau PET load and spatial distribution
por: Coomans, Emma M, et al.
Publicado: (2022)

Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
por: van Loenhoud, Anna Catharina, et al.
Publicado: (2019)

A clinical-radiological framework of the right temporal variant of frontotemporal dementia
por: Ulugut Erkoyun, Hulya, et al.
Publicado: (2020)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Is intracranial volume a suitable proxy for brain reserve?
por: van Loenhoud, Anna Catharina, et al.
Publicado: (2018)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u2roi74efnjoumsg1ntmgptcnm